Industry
Biotechnology
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Loading...
Open
2.45
Mkt cap
20M
Volume
50K
High
2.58
P/E Ratio
-0.02
52-wk high
21.40
Low
2.43
Div yield
N/A
52-wk low
2.43
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 9:13 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 07, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
September 27, 2024 | 4:15 pm
Portfolio Pulse from Dylan Berman
September 27, 2024 | 2:54 pm
Portfolio Pulse from Avi Kapoor
September 27, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 12:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.